A Study of Pocenbrodib Alone and in Combination With Darolutamide in People With Prostate Cancer

Full Title

PATHWAY: A Phase 1b/2a, Multicenter, Open-Label Study of Pocenbrodib as Monotherapy and in Combination With Darolutamide in Participants With Metastatic Castration-Resistant Prostate Cancer (mCRPC)

Purpose

To learn more about the purpose of this study and to find out who can join, please click here to visit ClinicalTrials.gov for a full clinical trial description.

Contact

For more information or to see if you can join this study, please call Dr. Nicholas Mai’s office at 646-888-4226.

Protocol
26-299
Phase
Phase I/II (phases 1 and 2 combined)
Investigator
Nicholas Mai
Co-Investigators
Ezra Rosen
Diseases
Genitourinary Cancer › Prostate Cancer
Locations
Memorial Sloan Kettering Cancer Center
Memorial Sloan Kettering Commack Nonna’s Garden Foundation Center
Memorial Sloan Kettering Basking Ridge
Memorial Sloan Kettering Westchester
Memorial Sloan Kettering Monmouth
Memorial Sloan Kettering Bergen
Memorial Sloan Kettering Nassau
ClinicalTrials.gov ID
NCT06785636
ClinicalTrials.gov
Visit ClinicalTrials.gov for full clinical trial description